Trial Profile
A Pilot Open-Label Study of the Efficacy and Safety of Imetelstat (GRN163L) in Myelofibrosis and Other Myeloid Malignancies
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 22 Sep 2021
Price :
$35
*
At a glance
- Drugs Imetelstat (Primary)
- Indications Essential thrombocythaemia; Myelofibrosis; Polycythaemia vera
- Focus Therapeutic Use
- Sponsors Geron Corporation; Janssen Research & Development
- 19 Jul 2018 Status changed from active, no longer recruiting to completed.
- 16 Jun 2017 Planned primary completion date changed from 1 May 2017 to 16 Jan 2019.
- 02 Dec 2016 Planned End Date changed from 1 May 2018 to 1 Jan 2019.